2025 年半年度报告 【披露时间】 浙江海翔药业股份有限公司 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人许国睿、主管会计工作负责人姚冰及会计机构负责人(会计主 管人员)周海燕声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司需遵守《深圳证券交易所上市公司自律监管指引第 3 号——行业信 息披露》中化工行业的披露要求 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 重要提示、目录和释义 | 2 | | --- | --- | | 第二节 公司简介和主要财务指标 | 8 | | 第三节 管理层讨论与分析 | 11 | | 第四节 公司治理、环境和社会 | 26 | | 第五节 重要事项 | 30 | | 第六节 股份变动及股东情况 | 36 | | 第七节 债券相关情况 | 41 | | 第八节 财务报告 | 42 | | 第九节 其他报送数据 | 177 | 备查文件目录 一、载 ...

Group 1 - The weight loss drug concept stocks experienced a decline in the afternoon trading session on August 28, with Meinuohua hitting the daily limit down [1] - MediXy and Kangyuan Pharmaceutical both fell over 7%, indicating a significant drop in their stock prices [1] - Other companies such as Kexing Pharmaceutical and Haixiang Pharmaceutical also reported notable declines in their stock performance [1]

Core Viewpoint - The stock price of Haixiang Pharmaceutical (002099) has decreased by 1.29% to 6.1 yuan as of August 18, 2025, with a trading volume of 180,100 shares and a turnover of 111 million yuan [1] Group 1: Company Performance and Financial Indicators - The company is expected to report a revenue of approximately 990 to 1,020 million yuan for the first half of 2025, representing a year-on-year decline of about 5% to 7% [1] - The projected net profit attributable to shareholders is estimated to be around 25 to 30 million yuan, indicating a significant year-on-year decrease of approximately 60% to 65% [1] - The gross profit margin is anticipated to be between 26.5% and 27.5%, which is a decline of about 4 to 5 percentage points compared to the same period last year [1] - The return on equity (ROE) is expected to be around 0.45% to 0.55% [1] Group 2: Market Activity and Investor Sentiment - On August 18, 2025, the net outflow of funds from major investors was 12.4 million yuan, while retail investors saw a net inflow of 8.28 million yuan [1] - The trading data indicates that speculative funds had a net inflow of 4.12 million yuan on the same day [1] Group 3: Management and Information Disclosure - The company emphasizes its compliance with relevant laws and regulations regarding information disclosure, stating that all information should be verified through designated media [1] - The company will release its 2025 semi-annual report on August 30, 2025, which will provide official performance data [1]

Core Viewpoint - The surge in the Shanghai Composite Index from around 3000 points in April to over 3600 points has led to a noticeable increase in the enthusiasm of listed companies for stock trading, with 57 companies announcing plans to use idle funds for securities investment [1] Group 1: Company Investment Trends - 57 listed companies have announced plans to use their idle funds for securities investment this year [1] - Companies such as Liou Co., Fangda Carbon, Seven Wolves, Tapa Group, Lianfa Co., Xiantan Co., and Zhejiang Yongqiang plan to invest over 1 billion yuan in securities [1] - Liou Co. leads with a proposed investment of 3 billion yuan, while Fangda Carbon and Seven Wolves plan to invest over 2 billion yuan each [1] Group 2: Company Profitability - Most companies engaging in stock trading are from traditional manufacturing sectors such as electric equipment, construction decoration, and steel [1] - Out of the 57 companies, 52 are expected to be profitable in 2024 [1] - The five companies projected to incur losses in 2024 include Buchang Pharma, Haixiang Pharma, Liou Co., Zhongke Jincai, and Baibang Technology [1] Group 3: Notable Losses - Buchang Pharma and Haixiang Pharma are expected to incur significant losses of 550 million yuan and 330 million yuan respectively in 2024, yet they still plan to allocate 30 million yuan and 70 million yuan for securities investment [1]

Core Viewpoint - The A-share market is experiencing a slight decline, with the Shanghai Composite Index down by 0.28% and a total trading volume of 878.86 billion yuan as of 10:30 AM [1] Group 1: Market Performance - The Shanghai Composite Index is at 3623.70 points, reflecting a decrease of 0.28% [1] - The total trading volume in the A-share market is reported at 878.86 billion yuan [1] Group 2: Moving Averages Analysis - Seven A-shares have seen their 5-day moving averages cross below their 10-day moving averages, indicating potential bearish trends [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Xintai (002294) with a distance of -0.51% - Wanbangde (002082) with a distance of -0.45% - Haixiang Pharmaceutical (002099) with a distance of -0.24% [1] Group 3: Individual Stock Performance - Xintai (002294) is down by 2.07% with a latest price of 47.79 yuan, which is 3.66% below its 10-day moving average [1] - Wanbangde (002082) has decreased by 0.95%, trading at 7.30 yuan, 2.93% below its 10-day moving average [1] - Haixiang Pharmaceutical (002099) is down by 0.33%, with a latest price of 6.08 yuan, 1.95% below its 10-day moving average [1] - Other stocks such as Bidai Pharmaceutical (688073) and Kewah (002335) also show declines in their respective prices and moving averages [1]

Group 1 - The stock price of Haixiang Pharmaceutical (002099) closed at 6.27 yuan on August 5, 2025, with a slight increase of 0.16% and a turnover rate of 0.96% [1] - On August 5, the net outflow of main funds was 877.82 million yuan, while retail investors saw a net inflow of 683.46 million yuan [2][4] - The company announced a share repurchase plan on April 9, 2025, with a total repurchase amount set between 150 million yuan and 300 million yuan, and a maximum repurchase price of 7.46 yuan per share [2] Group 2 - On August 5, 2025, Haixiang Pharmaceutical repurchased 850,000 shares through centralized bidding, accounting for 0.05% of the total share capital, with a total transaction amount of 5,326,664 yuan [2][4] - The company plans to continue the repurchase based on market conditions and will fulfill its information disclosure obligations [2]

Group 1 - The company Zhejiang Haixiang Pharmaceutical Co., Ltd. has approved a share repurchase plan using its own funds, with a total repurchase amount between RMB 150 million and RMB 300 million, and a maximum repurchase price of RMB 7.46 per share [1][2] - The first share repurchase involved buying back 850,000 shares, which represents 0.05% of the company's total share capital, with a total transaction amount of RMB 5,326,664, at prices ranging from RMB 6.24 to RMB 6.29 per share [1][2] - The repurchase plan is in compliance with relevant laws and regulations, and the company will continue to implement the plan based on market conditions within the specified timeframe [2]

证券日报网讯8月5日晚间，海翔药业（002099）发布公告称，2025年8月5日，公司首次通过股票回购专 用证券账户以集中竞价交易方式回购公司股份850，000股，占公司总股本的0.05%。 ...

Group 1 - Company HaiXiang Pharmaceutical announced a stock buyback of 850,000 shares, representing 0.05% of its total share capital, with a total transaction amount of approximately 5.33 million RMB [2] - The buyback occurred on August 5, 2025, with a maximum transaction price of 6.29 RMB per share and a minimum price of 6.24 RMB per share [2] Group 2 - For the year 2024, the revenue composition of HaiXiang Pharmaceutical is as follows: 70.59% from the pharmaceutical manufacturing sector, 28.47% from the dye industry, and 0.94% from other sources [2]

Core Viewpoint - Haishang Pharmaceutical (002099.SZ) announced a share buyback of 850,000 shares, representing 0.05% of the total share capital, at a total cost of approximately 5.33 million RMB [1] Group 1 - The company conducted the buyback through a dedicated securities account via centralized bidding [1] - The highest transaction price was 6.29 RMB per share, while the lowest was 6.24 RMB per share [1] - The total amount spent on the buyback was 5.326664 million RMB, excluding transaction fees [1]